About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to demonstrate additional health benefits beyond the numbers on a scale to get approved.

Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope for safer treatment options.

European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's administration is to avoid a period of economic pain for both sides from unilateral U.S. tariffs and EU countermeasures.

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.